{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:06:40Z","timestamp":1790690800504,"version":"4.1.0"},"reference-count":108,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>While certain forms of lymphoma\u2014such as classical Hodgkin lymphoma\u2014are classified as curable, with over half of all patients achieving remission following first-line therapy, a significant proportion of patients still suffer from relapsed or refractory disease. Through autologous stem cell transplantation (ASCT) and chimeric antigen receptor (CAR) T-cell therapy can significantly improve survival rates, their widespread clinical utility is constrained by logistical bottlenecks, manufacturing complexities, and high financial burdens. Similarly, antibody-drug conjugates and bispecific antibodies have achieved striking success against hematologic malignancies, but their clinical adoption is often hindered by the requirement for continuous infusion. Consequently, systemically delivered oncolytic viruses engineered to express immunotherapeutic elements have emerged as highly innovative alternatives. This review provides a comprehensive overview of the current landscape and outlines the therapeutic potential of oncolytic virotherapy in the fight against hematopoietic malignancies. We cross-examined a robust dataset of over 100 preclinical investigations to critically assess the therapeutic efficacy and safety profiles of more than ten diverse oncolytic virus platforms developed for blood cancer treatment, alongside multiple early-phase clinical trials that are completed or currently underway. By synthesizing these preclinical and clinical data, we propose three critical development pathways\u2014enhancing target specificity, arming viral vectors, and designing synergistic combination regimens\u2014to accelerate the translation of clinically viable oncolytic viruses for hematologic oncology.<\/jats:p>","DOI":"10.3389\/fmicb.2026.1925346","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:27:36Z","timestamp":1790688456000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic potential of oncolytic viruses in hematopoietic malignancies: from preclinical insights to clinical realities"],"prefix":"10.3389","volume":"17","author":[{"given":"Sebastian","family":"Erkens","sequence":"first","affiliation":[{"name":"Department of Human Medicine, Center for Biomedical Education and Research (ZBAF), Witten\/Herdecke University","place":["Witten, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawit Belai","family":"Ghebrehiwot","sequence":"additional","affiliation":[{"name":"Department of Human Medicine, Center for Biomedical Education and Research (ZBAF), Witten\/Herdecke University","place":["Witten, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Knierer","sequence":"additional","affiliation":[{"name":"Department of Human Medicine, Center for Biomedical Education and Research (ZBAF), Witten\/Herdecke University","place":["Witten, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tianjin Medical University Cancer Institute and Hospital","place":["Tianjin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Ehrhardt","sequence":"additional","affiliation":[{"name":"Department of Human Medicine, Center for Biomedical Education and Research (ZBAF), Witten\/Herdecke University","place":["Witten, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Human Medicine, Center for Biomedical Education and Research (ZBAF), Witten\/Herdecke University","place":["Witten, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1002\/1878-0261.12851","article-title":"Targeting immunogenic cell death in cancer","volume":"14","author":"Ahmed","year":"2020","journal-title":"Mol. Oncol."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s40425-017-0294-6","article-title":"Prospects for combined use of oncolytic viruses and CAR T-cells","volume":"5","author":"Ajina","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2147\/OV.S95250","article-title":"Newcastle disease virus, rituximab, and doxorubicin combination as anti-hematological malignancy therapy","volume":"5","author":"Al-Shammari","year":"2016","journal-title":"Oncolytic Virother"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.leukres.2009.05.020","article-title":"Susceptibility of mantle cell lymphomas to reovirus oncolysis","volume":"34","author":"Alain","year":"2010","journal-title":"Leuk. Res."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1484947","DOI":"10.3389\/fvets.2025.1484947","article-title":"Oncolytic potential of Newcastle disease virus in feline lymphoma cells: an in vitro evaluation","volume":"12","author":"Alves","year":"2025","journal-title":"Front. Vet. Sci."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"e011265","DOI":"10.1136\/jitc-2024-011265","article-title":"Single-cell analysis of oncolytic virotherapy in adult T-cell leukemia\/lymphoma","volume":"13","author":"An","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.3390\/cancers16152711","article-title":"H-1 parvovirus-induced Oncolysis and tumor microenvironment immune modulation in a novel heterotypic spheroid model of cutaneous T-cell lymphoma","volume":"16","author":"Angelova","year":"2024","journal-title":"Cancers (Basel)"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/mt.2009.78","article-title":"Oncolytic rat parvovirus H-1PV, a candidate for the treatment of human lymphoma: in vitro and in vivo studies","volume":"17","author":"Angelova","year":"2009","journal-title":"Mol. Ther."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.3389\/fonc.2017.00093","article-title":"The oncolytic Virotherapy era in Cancer management: prospects of applying H-1 parvovirus to treat blood and solid cancers","volume":"7","author":"Angelova","year":"2017","journal-title":"Front. Oncol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1365-2141.2007.06550.x","article-title":"Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma","volume":"137","author":"Au","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/BF01212880","article-title":"Preferential cytotoxic effect of Newcastle disease virus on lymphoma cells","volume":"122","author":"Bar-Eli","year":"1996","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/j.bbmt.2012.04.004","article-title":"Selective purging of human multiple myeloma cells from autologous stem cell transplantation grafts using oncolytic myxoma virus","volume":"18","author":"Bartee","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.clml.2015.12.005","article-title":"Myxoma virus induces ligand independent extrinsic apoptosis in human myeloma cells","volume":"16","author":"Bartee","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e70700","DOI":"10.7759\/cureus.70700","article-title":"Hypoxia-inducible factor 1-alpha (HIF-1alpha) and cancer: mechanisms of tumor hypoxia and therapeutic targeting","volume":"16","author":"Basheeruddin","year":"2024","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"11786","DOI":"10.1128\/JVI.01356-15","article-title":"Retargeting oncolytic vesicular stomatitis virus to human T-cell Lymphotropic virus type 1-associated adult T-cell leukemia","volume":"89","author":"Betancourt","year":"2015","journal-title":"J. Virol."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"562","DOI":"10.3390\/v11060562","article-title":"H-1 parvovirus as a Cancer-killing agent: past, present, and future","volume":"11","author":"Bretscher","year":"2019","journal-title":"Viruses"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/s1525-0016(02)00033-3","article-title":"An oncolytic measles virus engineered to enter cells through the CD20 antigen","volume":"7","author":"Bucheit","year":"2003","journal-title":"Mol. Ther."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1182\/blood-2013-09-528851","article-title":"Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity","volume":"123","author":"Castleton","year":"2014","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e006628","DOI":"10.1136\/jitc-2022-006628","article-title":"Vaccinating against cancer: getting to prime time","volume":"11","author":"Chang","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat. Med."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"6712","DOI":"10.1158\/1078-0432.CCR-11-0968","article-title":"Species D adenoviruses as oncolytics against B-cell cancers","volume":"17","author":"Chen","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"9837","DOI":"10.1158\/0008-5472.CAN-10-2650","article-title":"Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells","volume":"70","author":"Contag","year":"2010","journal-title":"Cancer Res."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/bloodadvances.2021006631","article-title":"Clinical activity of single-dose systemic oncolytic VSV virotherapy in patients with relapsed refractory T-cell lymphoma","volume":"6","author":"Cook","year":"2022","journal-title":"Blood Adv."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1182\/blood-2003-07-2233","article-title":"Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter","volume":"103","author":"Dingli","year":"2004","journal-title":"Blood"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/cancers13030544","article-title":"Measles virus as an oncolytic immunotherapy","volume":"13","author":"Engeland","year":"2021","journal-title":"Cancers (Basel)"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.molonc.2009.07.002","article-title":"Transcription factors down-stream of Ras as molecular indicators for targeting malignancies with oncolytic herpes virus","volume":"3","author":"Esfandyari","year":"2009","journal-title":"Mol. Oncol."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"3801","DOI":"10.32604\/or.2025.067824","article-title":"Immune checkpoint inhibitors combined with oncolytic Virotherapy: synergy, heterogeneity, and safety in Cancer treatment","volume":"33","author":"Feng","year":"2025","journal-title":"Oncol. Res."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s40259-022-00553-7","article-title":"Teserpaturev\/G47Delta: First Approval","volume":"36","author":"Frampton","year":"2022","journal-title":"BioDrugs"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"703878","DOI":"10.3389\/fonc.2021.703878","article-title":"Can targeting hypoxia-mediated acidification of the bone marrow microenvironment kill myeloma tumor cells?","volume":"11","author":"Gastelum","year":"2021","journal-title":"Front. Oncol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2620","DOI":"10.1016\/j.ymthe.2017.08.016","article-title":"Oncolytic H-1 parvovirus shows safety and signs of immunogenic activity in a first phase I\/IIa glioblastoma trial","volume":"25","author":"Geletneky","year":"2017","journal-title":"Mol. Ther."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1182\/blood.v97.12.3746","article-title":"Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice","volume":"97","author":"Grote","year":"2001","journal-title":"Blood"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/s41596-024-00985-1","article-title":"Tutorial: design, production and testing of oncolytic viruses for cancer immunotherapy","volume":"19","author":"Gujar","year":"2024","journal-title":"Nat. Protoc."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1158\/1078-0432.CCR-21-1020","article-title":"Phase 2 trial of oncolytic H-1 parvovirus therapy shows safety and signs of immune system activation in patients with metastatic pancreatic ductal adenocarcinoma","volume":"27","author":"Hajda","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1089\/biores.2012.0205","article-title":"Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia","volume":"1","author":"Hall","year":"2012","journal-title":"Biores Open Access"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"12971","DOI":"10.18632\/oncotarget.24191","article-title":"CD30-targeted oncolytic viruses as novel therapeutic approach against classical Hodgkin lymphoma","volume":"9","author":"Hanauer","year":"2018","journal-title":"Oncotarget"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41573-019-0029-0","article-title":"Optimizing oncolytic virotherapy in cancer treatment","volume":"18","author":"Harrington","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.omto.2016.12.004","article-title":"Oncolytic adenoviruses armed with tumor necrosis factor alpha and interleukin-2 enable successful adoptive cell therapy","volume":"4","author":"Havunen","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-020-00922-1","article-title":"Oncolytic viruses for cancer immunotherapy","volume":"13","author":"Hemminki","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.omto.2023.03.002","article-title":"Efficacy of coxsackievirus A21 against drug-resistant neoplastic B cells","volume":"29","author":"Holmes","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/sj.mt.6300020","article-title":"Infected cell carriers: a new strategy for systemic delivery of oncolytic measles viruses in cancer virotherapy","volume":"15","author":"Iankov","year":"2007","journal-title":"Mol. Ther."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1016\/j.ymthe.2020.09.041","article-title":"Oncolytic virus therapy with HSV-1 for hematological malignancies","volume":"29","author":"Ishino","year":"2021","journal-title":"Mol. Ther."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3390\/v13071406","article-title":"Targeting JAK\/STAT signaling antagonizes resistance to oncolytic Reovirus therapy driven by prior infection with HTLV-1 in models of T-cell lymphoma","volume":"13","author":"Islam","year":"2021","journal-title":"Viruses"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1007\/s12672-025-03062-5","article-title":"p53\/PD-L1 co-expression predicts poor prognosis in diffuse large B-cell lymphoma","volume":"16","author":"Jing","year":"2025","journal-title":"Discov. Oncol."},{"key":"ref44","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1080\/16078454.2021.1992117","article-title":"Could COVID-19 induce remission of acute leukemia?","volume":"26","author":"Kandeel","year":"2021","journal-title":"Hematology"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"3023","DOI":"10.1038\/onc.2011.478","article-title":"Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma","volume":"31","author":"Kelly","year":"2012","journal-title":"Oncogene"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"41275","DOI":"10.18632\/oncotarget.5753","article-title":"Junctional adhesion molecule-a is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus","volume":"6","author":"Kelly","year":"2015","journal-title":"Oncotarget"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.omto.2022.02.017","article-title":"NAD+ depletion enhances reovirus-induced oncolysis in multiple myeloma","volume":"24","author":"Kennedy","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.bbrc.2015.03.146","article-title":"Prevention of EBV lymphoma development by oncolytic myxoma virus in a murine xenograft model of post-transplant lymphoproliferative disease","volume":"462","author":"Kim","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"32174","DOI":"10.1038\/srep32174","article-title":"Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in multiple myeloma","volume":"6","author":"Lei","year":"2016","journal-title":"Sci. Rep."},{"key":"ref50","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-022-00634-4","article-title":"CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma","volume":"12","author":"Lei","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref51","doi-asserted-by":"publisher","first-page":"12160","DOI":"10.1128\/JVI.05703-11","article-title":"Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation","volume":"85","author":"Leveille","year":"","journal-title":"J. Virol."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/cgt.2011.14","article-title":"Enhancing VSV oncolytic activity with an improved cytosine deaminase suicide gene strategy","volume":"18","author":"Leveille","year":"","journal-title":"Cancer Gene Ther."},{"key":"ref53","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.3324\/haematol.2024.286923","article-title":"An oncolytic vaccinia virus expressing anti-CD47 nanobody exerts enhanced antitumor activity by mediating innate and adaptive immune cell infiltration and activation in the lymphoma tumor microenvironment","volume":"110","author":"Li","year":"2025","journal-title":"Haematologica"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"971674","DOI":"10.3389\/fimmu.2022.971674","article-title":"The gamble between oncolytic virus therapy and IFN","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"ref55","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s13045-020-00919-w","article-title":"Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy","volume":"13","author":"Marchica","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref56","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1089\/hum.2017.126","article-title":"CD20-CD19 bispecific CAR T cells for the treatment of B-cell malignancies","volume":"28","author":"Martyniszyn","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"ref57","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/cimb47040268","article-title":"Advances in gene therapy with oncolytic viruses and CAR-T cells and therapy-related groups","volume":"47","author":"Matsuzaka","year":"2025","journal-title":"Curr. Issues Mol. Biol."},{"key":"ref58","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.virusres.2014.05.025","article-title":"Success of measles virotherapy in ATL depends on type I interferon secretion and responsiveness","volume":"189","author":"Fernandez","year":"2014","journal-title":"Virus Res."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1038\/mt.2013.171","article-title":"Measles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy","volume":"21","author":"Miest","year":"2013","journal-title":"Mol. Ther."},{"key":"ref60","doi-asserted-by":"publisher","first-page":"211","DOI":"10.22088\/IJMCM.BUMS.8.3.211","article-title":"Caspase dependent and independent anti-hematological malignancy activity of AMHA1 attenuated Newcastle disease virus","volume":"8","author":"Mohammed","year":"2019","journal-title":"Int. J. Mol. Cell Med."},{"key":"ref61","doi-asserted-by":"publisher","first-page":"e009741","DOI":"10.1136\/jitc-2024-009741","article-title":"Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity","volume":"12","author":"Morita","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref62","first-page":"e001803","article-title":"Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche","volume-title":"J. Immunother. Cancer","author":"Muller","year":"2021"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1158\/1535-7163.MCT-17-0432","article-title":"Comparative oncology evaluation of intravenous recombinant oncolytic vesicular stomatitis virus therapy in spontaneous canine Cancer","volume":"17","author":"Naik","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref64","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1038\/leu.2012.70","article-title":"Curative one-shot systemic virotherapy in murine myeloma","volume":"26","author":"Naik","year":"2012","journal-title":"Leukemia"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.exphem.2006.03.002","article-title":"Oncolytic measles virus targets high CD46 expression on multiple myeloma cells","volume":"34","author":"Ong","year":"2006","journal-title":"Exp. Hematol."},{"key":"ref66","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/leu.2015.88","article-title":"Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia","volume":"29","author":"Parrish","year":"2015","journal-title":"Leukemia"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"141","DOI":"10.23750\/abm.v91i3.10141","article-title":"Oncolytic effect of SARS-CoV2 in a patient with NK lymphoma","volume":"91","author":"Pasin","year":"2020","journal-title":"Acta Biomed"},{"key":"ref68","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/mt.2011.44","article-title":"Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights","volume":"19","author":"Patel","year":"2011","journal-title":"Mol. Ther."},{"key":"ref69","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1182\/blood-2002-07-2195","article-title":"Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker","volume":"101","author":"Peng","year":"2003","journal-title":"Blood"},{"key":"ref70","doi-asserted-by":"publisher","first-page":"764698","DOI":"10.3389\/fcell.2021.764698","article-title":"The bone marrow microenvironment mechanisms in acute myeloid leukemia","volume":"9","author":"Pimenta","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref71","first-page":"8366","article-title":"The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase\/uracil phosphoribosyltransferase suicide gene","volume":"63","author":"Porosnicu","year":"2003","journal-title":"Cancer Res."},{"key":"ref72","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/sj.leu.2405034","article-title":"Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7\/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis","volume":"22","author":"Qian","year":"2008","journal-title":"Leukemia"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.ccell.2020.12.022","article-title":"Oncolytic virotherapy-mediated anti-tumor response: a single-cell perspective","volume":"39","author":"Ramelyte","year":"2021","journal-title":"Cancer Cell"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1038\/s41417-021-00359-9","article-title":"Combination therapy with CAR T cells and oncolytic viruses: a new era in cancer immunotherapy","volume":"29","author":"Rezaei","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"ref75","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.mayocp.2014.04.003","article-title":"Remission of disseminated cancer after systemic oncolytic virotherapy","volume":"89","author":"Russell","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1038\/mt.2013.91","article-title":"BCL-2 inhibitors sensitize therapy-resistant chronic lymphocytic leukemia cells to VSV oncolysis","volume":"21","author":"Samuel","year":"2013","journal-title":"Mol. Ther."},{"key":"ref77","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/v8010003","article-title":"Newcastle disease virus: potential therapeutic application for human and canine lymphoma","volume":"8","author":"Sanchez","year":"2015","journal-title":"Viruses"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/gt.2009.39","article-title":"VSV virotherapy improves chemotherapy by triggering apoptosis due to proteasomal degradation of Mcl-1","volume":"16","author":"Schache","year":"2009","journal-title":"Gene Ther."},{"key":"ref79","doi-asserted-by":"publisher","first-page":"105219","DOI":"10.1016\/j.ebiom.2024.105219","article-title":"Biomarker screen for efficacy of oncolytic virotherapy in patient-derived pancreatic cancer cultures","volume":"105","author":"Schafer","year":"2024","journal-title":"EBioMedicine"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1182\/blood-2015-06-652503","article-title":"Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia","volume":"127","author":"Shen","year":"2016","journal-title":"Blood"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/bs.ircmb.2023.05.001","article-title":"Oncolytic viruses in hematological malignancies: hijacking disease biology and fostering new promises for immune and cell-based therapies","volume":"379","author":"Sousa-Pimenta","year":"2023","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref83","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1158\/1535-7163.MCT-15-0240-T","article-title":"Histone deacetylase inhibitors enhance the therapeutic potential of Reovirus in multiple myeloma","volume":"15","author":"Stiff","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"ref84","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/cgt.2012.56","article-title":"Sindbis viral vectors target hematopoietic malignant cells","volume":"19","author":"Suzme","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"ref85","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/cas.12324","article-title":"Enhanced susceptibility of B lymphoma cells to measles virus by Epstein-Barr virus type III latency that upregulates CD150\/signaling lymphocytic activation molecule","volume":"105","author":"Takeda","year":"2014","journal-title":"Cancer Sci."},{"key":"ref86","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/bmt.2013.130","article-title":"Reovirus as a successful ex vivo purging modality for multiple myeloma","volume":"49","author":"Thirukkumaran","year":"2014","journal-title":"Bone Marrow Transplant."},{"key":"ref87","doi-asserted-by":"publisher","first-page":"4962","DOI":"10.1158\/1078-0432.CCR-11-3085","article-title":"Reovirus as a viable therapeutic option for the treatment of multiple myeloma","volume":"18","author":"Thirukkumaran","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref88","doi-asserted-by":"publisher","first-page":"8487","DOI":"10.1128\/JVI.00851-08","article-title":"Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis","volume":"82","author":"Tumilasci","year":"2008","journal-title":"J. Virol."},{"key":"ref89","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/BF01198099","article-title":"The effect of a mesogenic and a lentogenic Newcastle disease virus strain on Burkitt lymphoma Daudi cells","volume":"121","author":"Tzadok-David","year":"1995","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref90","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1038\/gt.2010.103","article-title":"Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics","volume":"17","author":"Ungerechts","year":"2010","journal-title":"Gene Ther."},{"key":"ref91","doi-asserted-by":"publisher","first-page":"490","DOI":"10.18632\/oncotarget.28205","article-title":"Transplantation of autologous bone marrow pre-loaded ex vivo with oncolytic myxoma virus is efficacious against drug-resistant Vk*MYC mouse myeloma","volume":"13","author":"Villa","year":"2022","journal-title":"Oncotarget"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1002\/jgm.1326","article-title":"E1B 55-kDa deleted, Ad5\/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies","volume":"11","author":"Wang","year":"2009","journal-title":"J. Gene Med."},{"key":"ref93","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2147\/OTT.S209312","article-title":"Embelin promotes oncolytic vaccinia virus-mediated antitumor immunity through disruption of IL-6\/STAT3 signaling in lymphoma","volume":"13","author":"Wang","year":"2020","journal-title":"Onco. Targets Ther."},{"key":"ref94","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1002\/jha2.546","article-title":"Diffuse large B-cell lymphoma with phenotype switch, anaplastic features and aberrant T-cell marker expression during disease evolution","volume":"3","author":"Wang","year":"2022","journal-title":"EJHaem"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ymthe.2020.10.023","article-title":"Clinical CAR-T cell and oncolytic Virotherapy for Cancer treatment","volume":"29","author":"Watanabe","year":"2021","journal-title":"Mol. Ther."},{"key":"ref96","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1089\/hum.2011.071","article-title":"Comparison of adenoviruses as oncolytics and cancer vaccines in an immunocompetent B cell lymphoma model","volume":"22","author":"Weaver","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"ref97","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/s41417-020-0176-9","article-title":"Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and\/or CD40","volume":"27","author":"Wenthe","year":"2020","journal-title":"Cancer Gene Ther."},{"key":"ref98","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1007\/s00262-021-02895-7","article-title":"Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40\/4-1BB using oncolytic viral gene therapy","volume":"70","author":"Wenthe","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref99","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1007\/s00262-026-04396-x","article-title":"IL-18-armed oncolytic vaccinia virus remodels the suppressive microenvironment via macrophage and Treg modulation in lymphoma","volume":"75","author":"Wu","year":"2026","journal-title":"Cancer Immunol. Immunother."},{"key":"ref100","doi-asserted-by":"publisher","first-page":"987","DOI":"10.3892\/or.2021.7942","article-title":"Beclin1-armed oncolytic vaccinia virus enhances the therapeutic efficacy of R-CHOP against lymphoma in vitro and in vivo","volume":"45","author":"Xie","year":"2021","journal-title":"Oncol. Rep."},{"key":"ref101","doi-asserted-by":"publisher","first-page":"110171","DOI":"10.1016\/j.virol.2024.110171","article-title":"Human umbilical cord mesenchymal stem cell exosomes deliver potent oncolytic reovirus to acute myeloid leukemia cells","volume":"598","author":"Yang","year":"2024","journal-title":"Virology"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1053\/j.seminoncol.2021.11.001","article-title":"Complete response in a frail patient with high-grade B-cell lymphoma to only one cycle of R-CHOP or to prolonged COVID-19?","volume":"48","author":"Yilmaz","year":"2021","journal-title":"Semin. Oncol."},{"key":"ref103","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s40425-019-0664-3","article-title":"Molecular and metabolic pathways mediating curative treatment of a non-Hodgkin B cell lymphoma by Sindbis viral vectors and anti-4-1BB monoclonal antibody","volume":"7","author":"Yu","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"897561","DOI":"10.3389\/fonc.2022.897561","article-title":"In situ tumor vaccine expressing anti-CD47 antibody enhances antitumor immunity","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"ref105","doi-asserted-by":"publisher","first-page":"2259126","DOI":"10.1080\/08916934.2023.2259126","article-title":"Oncolytic virus oHSV2 combined with PD-1\/PD-L1 inhibitors exert antitumor activity by mediating CD4 + T and CD8 + T cell infiltration in the lymphoma tumor microenvironment","volume":"56","author":"Zhang","year":"2023","journal-title":"Autoimmunity"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"1696105","DOI":"10.3389\/fonc.2026.1696105","article-title":"Research progress on resistance mechanisms to CAR-T cell therapy in diffuse large B-cell lymphoma","volume":"16","author":"Zhang","year":"2026","journal-title":"Front. Oncol."},{"key":"ref107","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.3390\/jcm12031098","article-title":"Talimogene laherparepvec (T-VEC): a review of the recent advances in cancer therapy","volume":"12","author":"Zhang","year":"2023","journal-title":"J. Clin. Med."},{"key":"ref108","doi-asserted-by":"publisher","first-page":"637","DOI":"10.3892\/or.2011.1306","article-title":"Evaluation of HSV-1 and adenovirus vector-mediated infection, replication and cytotoxicity in lymphoma cell lines","volume":"26","author":"Zhang","year":"2011","journal-title":"Oncol. Rep."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1925346\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:27:38Z","timestamp":1790688458000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2026.1925346\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":108,"alternative-id":["10.3389\/fmicb.2026.1925346"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2026.1925346","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1925346"}}